2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer

Xiaozheng Kang, Jianjun Qin, Ruixiang Zhang, Zhen Wang, Qingfeng Zheng, Yong Li, Jianping Xu, Jing Huang, Xin Wang, Zhouguang Hui, Liyan Xue, Yousheng Mao, Yin Li, Jie He, Chun Chen, Haiquan Chen, Ke-Neng Chen, Long-Qi Chen, Maoyong Fu, Junke Fu, Qing Geng, Taiqian Gong, Shiping Guo, Yongtao Han, Yi He, Jian Hu, Hongjing Jiang, Jie Jiang, Yuequan Jiang, Mingqiang Kang, Jianqun Ma, Shaohua Ma, Yongde Liao, Hecheng Li, Shanqing Li, Zhigang Li, Shuoyan Liu, Yang Liu, Guibin Qiao, Lijie Tan, Hui Tian, Gaofeng Zhao, Jun Zhao, Shiying Zheng, Yongan Zhou, Magnus Nilsson, Francisco Schlottmann, Riccardo Rosati, Cascinu Stefano, Philip Wai-yan Chiu, Neil B. Newman, Noriyuki Hirahara, Dae Joon Kim, Rutika Mehta, Kimberly L. Johung, Michael Cecchini, Shane Lloyd, Kenneth Meredith

[1]  Kisha Mitchell,et al.  Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Ajani,et al.  Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. , 2021 .

[3]  J. Ajani,et al.  Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. , 2021, The New England journal of medicine.

[4]  W. Mao,et al.  Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma , 2021, Annals of surgery.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  E. D. Geijsen,et al.  Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT) , 2021, Clinical Cancer Research.

[7]  S. Yeung,et al.  Neoadjuvant PD-1 blockade in combination with chemotherapy for patients with resectable esophageal squamous cell carcinoma. , 2021 .

[8]  Q. Fan,et al.  Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. , 2021, Journal of Clinical Oncology.

[9]  Yuyan Zheng,et al.  Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). , 2020, European journal of cancer.

[10]  David R. Jones,et al.  Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. , 2020, The Journal of thoracic and cardiovascular surgery.

[11]  Mengxia Li,et al.  415 Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study , 2020, Journal for ImmunoTherapy of Cancer.

[12]  N. Sun,et al.  175P A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC) , 2020 .

[13]  Sung-Bae Kim,et al.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Ajani,et al.  LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study , 2020 .

[15]  M. Shah,et al.  LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study , 2020 .

[16]  Y. Hu,et al.  1058P A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC) , 2020 .

[17]  J. Ajani,et al.  LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study , 2020 .

[18]  S. Oh,et al.  LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study , 2020 .

[19]  Jian-Hua Fu,et al.  Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010. , 2020, European journal of cancer.

[20]  David T. W. Tzeng,et al.  The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer , 2020, Cancer Immunology Research.

[21]  Y. Ba,et al.  Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.

[22]  Joe Y. Chang,et al.  Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Shu-geng Gao,et al.  Analysis of a registry database for esophageal cancer from high-volume centers in China. , 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[24]  H. Ishwaran,et al.  Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma. , 2019, Annals of surgery.

[25]  D. Altmann,et al.  Antibiotic therapy and outcome from immune-checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[26]  M. Westerhoff,et al.  Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey , 2019, Modern Pathology.

[27]  H. Daiko,et al.  FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma , 2019, Annals of Oncology.

[28]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[29]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[30]  Jong Hoon Kim,et al.  A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). , 2019, Journal of Clinical Oncology.

[31]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.

[32]  R. Hales,et al.  Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. , 2019, Journal of Clinical Oncology.

[33]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[34]  S. Perkins,et al.  Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study. , 2018 .

[35]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[36]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[38]  S. Barni,et al.  Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[40]  A. Giobbie-Hurder,et al.  Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements , 2013, Clinical Cancer Research.

[41]  Y. Qiao,et al.  Occupational and environmental cancer incidence and mortality in China. , 2012, Occupational medicine.

[42]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[43]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[44]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[45]  Jeffrey S. Morris,et al.  Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation , 2005, Cancer.

[46]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[47]  G. Noël,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy , 2002 .

[48]  R. Ginsberg,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[50]  N. Dalkey,et al.  An Experimental Application of the Delphi Method to the Use of Experts , 1963 .

[51]  H. Ishwaran,et al.  Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.